National Clinical Research Platform Assessing Molecular Testing, Treatment, and Outcomes in Non-Small and Small Cell Lung Cancer Patients
Led by AIO-Studien-gGmbH · Updated on 2026-10-09
14500
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a large, open, non-interventional clinical research platform to study patients with non-small cell lung cancer NSCLC and small cell lung cancer SCLC in Germany. The study aims to assess molecular biomarker testing, treatments, and patient outcomes to better understand real-life care for these lung cancer types. A key focus is on molecular biomarker testing before starting first-line treatment in patients with advanced or metastatic NSCLC, helping to evaluate and improve care quality.
This observational study collects detailed data on patient characteristics, biomarker testing including retesting, treatment decisions, various systemic anticancer therapies, radiotherapies, surgeries, supportive therapies, and disease progression. Data are gathered at baseline and updated at least every three months. The study includes several patient groups based on cancer stage and type, including those receiving systemic therapy, surgery, radiotherapy, or best supportive care. A decentralized tissue repository is also being established for future scientific biomarker research.
Participants will provide written informed consent and complete patient-reported outcomes assessing quality of life, physical and psychological well-being, and anxietydepression. Data collection continues over three years with updates on treatment response, progression-free and overall survival, and other health-related measures. This comprehensive approach aims to improve understanding of lung cancer treatment and patient experience in routine practice.
CONDITIONS
Brief Title
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Research Team
A
Annika Groth
P
Paula Ludwig
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Able to understand and willing to sign written informed consent
Willing to complete patient-reported outcome assessments
Confirmed non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)
For NSCLC Stage IV patients: Stage IV disease, starting first-line systemic therapy, consent within four weeks of treatment start
For NSCLC Stage I-III patients: Stage I-III disease, consent within four weeks of first anti-tumor treatment start or within three months after surgery
For SCLC patients: Starting first anti-tumor treatment, consent within four weeks of treatment start
Receiving systemic therapy, radiotherapy, surgery, or best supportive care
You will not qualify if you...
None specified
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Data Collection
Duration - Up to 3 years
Participants provide baseline information on demographics, clinical status, tumor characteristics, biomarker testing, treatments, and disease outcomes. Data is updated regularly throughout the study.
Data updated at least every three months
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Similar Trials
Study of 7T Brain MRI to Detect Small Brain Metastases in Adults With Small-cell Lung Cancer Who Decline Preventive Brain Radiation
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study on Using Pre-treatment Tumor Biopsies to Predict Response to PD-1PD-L1 Immunotherapy in Various Cancers
Study of OM-RCA-01 Antibody for Safety and Effectiveness in Treating Metastatic Cancers with FGFR1
BIO 300 with Thoracic Radiation to Reduce Lung Toxicity in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease
Evaluating Hospital-at-Home Care for Monitoring Tarlatamab Treatment in Extensive Stage Small Cell Lung Carcinoma
Study of IDE849 Treatment in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer and Neuroendocrine Carcinomas
Study of MGC026 with or without Pembrolizumab in Adults with Advanced Solid Tumors Using Intravenous Infusion
Phase II Study of Stereotactic Radiosurgery for Brain Metastases in Adults with Small Cell Lung Cancer
Phase 1 Study of NN3201, a c-Kit Targeting Antibody-Drug Combination, for Advanced or Metastatic Solid Tumors Expressing c-Kit
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
Martin Sebastian, Wilfried E E Eberhardt, Eyck von der Heyde...
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch...